Form 4 for BSX Boston Scientific
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-03 · accession 0001225208-24-000380 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-04 | 2024-01-03 | BSX | Mirviss Jeffrey B. | EVP, Pres, Periph Intervent | S - Sale | $57.82 | -11.9K | 56.6K | -17% | -$689.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-03 | S | D | 11,931 | $57.82 | 56,588 | D | — | — | (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $57.65 to $58.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |